Delafloxacin
Delafloxacin (developmental code name RX-3341) is a fluoroquinolone antibiotic being developed by Rib-X Pharmaceuticals, Inc. It is more active (lower MIC90) than other quinolones against Gram-positive bacteria such as MRSA. In contrast to most approved fluoroquinolones, which are zwitterionic, delafloxacin has an anionic character, which results in a 10-fold increase in delafloxacin accumulation in both bacteria and cells at acidic pH. This property is believed to confer to delafloxacin an advantage for the eradication of Staphylococcus aureus in acidic environments, including intracellular infections.
Wikipage redirect
primaryTopic
Delafloxacin
Delafloxacin (developmental code name RX-3341) is a fluoroquinolone antibiotic being developed by Rib-X Pharmaceuticals, Inc. It is more active (lower MIC90) than other quinolones against Gram-positive bacteria such as MRSA. In contrast to most approved fluoroquinolones, which are zwitterionic, delafloxacin has an anionic character, which results in a 10-fold increase in delafloxacin accumulation in both bacteria and cells at acidic pH. This property is believed to confer to delafloxacin an advantage for the eradication of Staphylococcus aureus in acidic environments, including intracellular infections.
has abstract
Delafloxacin (developmental co ...... ding intracellular infections.
@en
ATC prefix
CAS number
189279-58-1
FDA UNII code
6315412YVF
IUPAC name
1-(6-amino-3,5-difluoro-2-pyri ...... xo-quinoline-3-carboxylic acid
@en
PubChem
thumbnail
Wikipage page ID
21,265,986
Wikipage revision ID
723,298,554
ChEMBL
ChemSpiderID
legal status
Investigational
molecular weight
comment
Delafloxacin (developmental co ...... ding intracellular infections.
@en
label
Delafloxacin
@en